ELAVL1 and metabolic dysfunction-associated steatotic liver disease: Finally, we discuss both the potential benefits and challenges of targeting HuR in MASLD and related metabolic disorders, emphasizing the need for cell-specific strategies that preserve HuR’s protective roles while mitigating its pathogenic effects.